Filtered By:
Condition: Hemorrhagic Stroke
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date.
Order by Relevance | Date
Total 119 results found since Jan 2013.
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy
CONCLUSIONS: In stabilised acute myocardial infarction patients, unguided de-escalation from ticagrelor to clopidogrel was associated with a lower rate of net adverse clinical outcomes irrespective of HBR status. The effect of de-escalation of P2Y12 inhibition on reducing haemorrhagic events was greater in patients with HBR.PMID:37724337 | DOI:10.4244/EIJ-D-23-00427
Source: EuroIntervention - September 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Min Chul Kim Sung Gyun Ahn Kyung Hoon Cho Doo Sun Sim Young Joon Hong Ju Han Kim Myung Ho Jeong Jun-Won Lee Young-Jin Youn Hee-Yeol Kim Ki-Dong Yoo Doo-Soo Jeon Eun-Seok Shin Young-Hoon Jeong Kiyuk Chang Youngkeun Ahn Source Type: research
Intracranial haemorrhage in acute myocardial infarction: A rare but dramatic complication
The shift from thrombolysis to primary percutaneous coronary intervention (PCI) and the use of multidrug antithrombotic therapy in the management of acute myocardial infarction (AMI) have led to both a substantial improvement in outcomes and a reduction in bleeding complications [1,2]. In particular, in AMI, the rate of haemorrhagic stroke, the most dreaded haemorrhagic complication, decreased by 50% from 1998 to 2008 [1]. Despite its low incidence, intracranial haemorrhage (ICH) is often devastating, being associated with severe disability and high mortality rates.
Source: International Journal of Cardiology - August 29, 2023 Category: Cardiology Authors: Filippo Trombara, Nicola Cosentino, Giancarlo Marenzi Tags: Editorial Source Type: research
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
A Small Increase in Serum Creatinine within 48 h of Hospital Admission Is an Independent Predictor of In-Hospital Adverse Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Findings from the Improving Care for Cardiovascular Disease in the China Project
CONCLUSION: A small increase in Scr during hospitalization in patients with STEMI undergoing primary PCI that does not meet the criteria for AKI is a risk factor for in-hospital adverse outcomes. This effect is maintained in patients with normal Scr at hospitalization. Trial Registration. Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02306616.PMID:37025394 | PMC:PMC10072956 | DOI:10.1155/2023/1374206
Source: Cardiology Research and Practice - April 7, 2023 Category: Cardiology Authors: Jiajia Zhu Wenxian Liu Jiang Li Changsheng Ma Dong Zhao Source Type: research
Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research
